GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago. These figures are ...

(Reuters) - GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts and dual sourcing for its medicines, but offered few details.

As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the British drug giant feels prepared for any challenges that U.S. drug import ...

GSK is 'well positioned' to deal with the potential implications of any new US tariffs on pharma imports, the group said on Wednesday. President Donald Trump slapped a 10 per cent baseline ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. GSK has three segments: Specialty Medicines (HIV, Oncology, Immunology/Respiratory and Other), Vaccines ...

Royalty Income for 2025: Expected to be GBP 750 to 800 million. GSK PLC (NYSE:GSK) reported a 4% increase in group sales and a 5% rise in operating profit, demonstrating the strength and resilience of ...

Drugmaker GSK (GlaxoSmithKline) has said it is “well positioned” to cope with any financial impact from changes to US tariff rules. It came as the FTSE 100 giant revealed a rise in sales as ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

GSK posted higher profit as its cancer treatments lifted sales ahead of analysts' expectations, offsetting lower vaccine sales on weak demand in the U.S. The British pharmaceutical giant said ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.